Evidence map›Paper›PMID 41024397›Full record

ArticleNeuropsychopharmacology reports2025

Rapid-Onset Therapeutic Effects of Delta Opioid Receptor Agonists on Depression-Like Behaviors Induced by Chronic Social Defeat Stress.

Akihisa Tokuda, Yasuyuki Nagumo, Keita Kajino, Keita Iio, Katsuyasu Sakurai, Seiya Mizuno, Akiyoshi Saitoh, Tsuyoshi Saitoh, Hiroshi Nagase

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropsychopharmacology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Akihisa TokudaInternational Institute for Integrative Sleep Medicine (IIIS), University of Tsukuba, Tsukuba, Ibaraki, Japan.
Yasuyuki NagumoInternational Institute for Integrative Sleep Medicine (IIIS), University of Tsukuba, Tsukuba, Ibaraki, Japan.
Keita KajinoInternational Institute for Integrative Sleep Medicine (IIIS), University of Tsukuba, Tsukuba, Ibaraki, Japan.
Keita IioInternational Institute for Integrative Sleep Medicine (IIIS), University of Tsukuba, Tsukuba, Ibaraki, Japan.
Katsuyasu SakuraiInternational Institute for Integrative Sleep Medicine (IIIS), University of Tsukuba, Tsukuba, Ibaraki, Japan.
Seiya MizunoLaboratory Animal Resource Center and Trans-Border Medical Research Center, University of Tsukuba, Tsukuba, Japan.
Akiyoshi SaitohLaboratory of Pharmacology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Japan.ORCID https://orcid.org/0000-0001-8617-2441
Tsuyoshi SaitohInternational Institute for Integrative Sleep Medicine (IIIS), University of Tsukuba, Tsukuba, Ibaraki, Japan.ORCID https://orcid.org/0000-0001-6105-6292
Hiroshi NagaseInternational Institute for Integrative Sleep Medicine (IIIS), University of Tsukuba, Tsukuba, Ibaraki, Japan.ORCID https://orcid.org/0000-0003-0428-3979

Funding

Fusion Oriented REsearch for disruptive Science and Technology JPMJFR2109Japan Agency for Medical Research and Development JP21zf0127005Japan Foundation for Applied Enzymology 16H007Japan Society for the Promotion of Science 20H03361Japan Society for the Promotion of Science 21B209Japan Society for the Promotion of Science 22K21351Japan Society for the Promotion of Science 23H02100Top Runners in Strategy of Transborder Advanced Research (TRiSTAR) program for Young Researchers by the MEXTUniversity Fellowship Creation Project for Creating Scientific and Technological Innovation JPMJFS2106
6 · The paper itself

Abstract

Depression is prevalent, yet conventional antidepressants often require time to produce therapeutic effects. Therefore, novel antidepressants with a more rapid onset of action are urgently needed. This study investigated the potential of δ opioid receptor (DOP) agonists as fast-acting antidepressants, comparing their efficacy with that of existing treatments. We utilized the chronic social defeat stress (CSDS) model, which closely mimics clinical depressive symptoms, to evaluate the therapeutic effects of DOP agonists (SNC80, KNT-127) and paroxetine, a selective serotonin reuptake inhibitor. Mice exposed to CSDS for 10 days showed social avoidance toward aggressor mice along with generalized depression and anxiety-like behaviors. Both DOP agonists demonstrated dose-dependent therapeutic effects at 1-10 mg/kg and showed improvements within 10-14 days of chronic administration. In contrast, paroxetine alleviated these symptoms after 28 days of treatment. These findings suggest that DOP agonists may offer a faster-acting alternative to current antidepressant therapies.

Indexed as

Antidepressive AgentsDepressionReceptors, Opioid, deltaSocial DefeatStress, PsychologicalAnimalsBenzamidesDisease Models, AnimalDose-Response Relationship, DrugMaleMiceMorphinansParoxetinePiperazines4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-N,N-diethylbenzamideAntidepressive AgentsBenzamidesKNT 127MorphinansParoxetinePiperazinesReceptors, Opioid, deltaanxietychronic social defeat stressdepressionopioid delta receptor agonistsocial behavior

Identifiers

PMID41024397
PMCPMC12479375

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.